HAO News & Events

Haoxi Health Technology announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of approximately $6.5M of the company's securities, including 9M Class A ordinary shares, par value $0.0025 per share and 16,999,998 pre-funded warrants, at a purchase price of 25c per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for shares, less the exercise price of $0.0026 per share. Each pre-funded warrant is exercisable to purchase 10.355 shares. The aggregate gross proceeds to the company of this offering are expected to be approximately $6.5M, before deducting placement agent commissions and other offering expenses. The transaction is expected to close on or about May 12, subject to the satisfaction of customary closing conditions. The company intends to use the net proceeds from this offering for working capital and general corporate purposes. Univest Securities is acting as the sole placement agent.

Haoxi Health Technology (HAO) and Eaglepoint AI, a subsidiary of Global Mofy AI Limited (GMM), jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.

Haoxi Health Technology announced that Beijing Haoxi Digital Technology has launched its customized livestreaming agency strategy and is progressing partnership discussions on personalized livestreaming agency services with several long-term clients of medical aesthetics. Driven by the growing demand for personalized and high-quality services in the healthcare and medical aesthetics sectors, and in response to evolving macro-consumption trends, Haoxi Beijing has officially launched its livestreaming agency services. This offering comes after the Company's establishment of a stable advertising delivery model built on long-term client servicing experience. The new service covers a full-cycle, closed-loop approach-from pre-campaign planning and livestream initiation to post-campaign analysis-tailored especially for the booming "light medical aesthetics" segment, including laser and injection-based treatments. It is designed to integrate evolving consumer behaviors with platform-specific operational strategies.

Haoxi Health Technology received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's Class A ordinary shares, par value $0.0025 each to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from January 27, 2025, to February 7, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.